In Case You Missed It
Updated Thursday, April 27, 2017
Guidelines
HCV Guidelines
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.
Homepage - HCV Guidelines
HCV Guidelines
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV.
Homepage - HCV Guidelines
Stay current with all guideline updates, click here.
What’s New and Updates/Changes
This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance.
Global Changes Occurring throughout the document:
- RAV changed to RAS
- Standardized renal function parameter from CrCI to eGFR
- Includes new recommendation to shorten the duration of ledipasvir (90 mg)/sofosbuvir (400 mg) in patients without cirrhosis to 8 weeks for non-black, HIV-uninfected, and whose HCV RNA is <6 million IU/mL
- Updated grading of sofosbuvir/velpatasvir for genotypes 5 and 6
- Language added related to recent data regarding 8 weeks of PrOD for genotype 1b with early stage fibrosis
Decompensated:
Renal:
Upcoming Updates:
- Guidance will be forthcoming regarding treatment of adolescents living with chronic HCV given recent FDA-approvals
No comments:
Post a Comment